542 related articles for article (PubMed ID: 23530502)
1. Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis.
Domhan S; Schwager C; Wei Q; Muschal S; Sommerer C; Morath C; Wick W; Maercker C; Debus J; Zeier M; Huber PE; Abdollahi A
Curr Pharm Des; 2014; 20(1):88-100. PubMed ID: 23530502
[TBL] [Abstract][Full Text] [Related]
2. Akt and p53 are potential mediators of reduced mammary tumor growth by cloroquine and the mTOR inhibitor RAD001.
Loehberg CR; Strissel PL; Dittrich R; Strick R; Dittmer J; Dittmer A; Fabry B; Kalender WA; Koch T; Wachter DL; Groh N; Polier A; Brandt I; Lotz L; Hoffmann I; Koppitz F; Oeser S; Mueller A; Fasching PA; Lux MP; Beckmann MW; Schrauder MG
Biochem Pharmacol; 2012 Feb; 83(4):480-8. PubMed ID: 22142888
[TBL] [Abstract][Full Text] [Related]
3. The mTOR inhibitor RAD001 sensitizes tumor cells to the cytotoxic effect of carboplatin in breast cancer in vitro.
Liu H; Zang C; Schefe JH; Schwarzlose-Schwarck S; Regierer AC; Elstner E; Schulz CO; Scholz C; Possinger K; Eucker J
Anticancer Res; 2011 Sep; 31(9):2713-22. PubMed ID: 21868512
[TBL] [Abstract][Full Text] [Related]
4. Everolimus (RAD001) sensitizes prostate cancer cells to docetaxel by down-regulation of HIF-1α and sphingosine kinase 1.
Alshaker H; Wang Q; Kawano Y; Arafat T; Böhler T; Winkler M; Cooper C; Pchejetski D
Oncotarget; 2016 Dec; 7(49):80943-80956. PubMed ID: 27821815
[TBL] [Abstract][Full Text] [Related]
5. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
6. Autophagy inhibition enhances RAD001-induced cytotoxicity in human bladder cancer cells.
Lin JF; Lin YC; Yang SC; Tsai TF; Chen HE; Chou KY; Hwang TI
Drug Des Devel Ther; 2016; 10():1501-13. PubMed ID: 27143856
[TBL] [Abstract][Full Text] [Related]
7. Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.
Chan SL; Wong CH; Lau CP; Zhou Q; Hui CW; Lui VW; Ma BB; Chan AT; Yeo W
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1417-25. PubMed ID: 23546591
[TBL] [Abstract][Full Text] [Related]
8. mTOR inhibitor RAD001 (everolimus) induces apoptotic, not autophagic cell death, in human nasopharyngeal carcinoma cells.
Cai Y; Xia Q; Su Q; Luo R; Sun Y; Shi Y; Jiang W
Int J Mol Med; 2013 Apr; 31(4):904-12. PubMed ID: 23426850
[TBL] [Abstract][Full Text] [Related]
9. Enhanced radiation damage of tumor vasculature by mTOR inhibitors.
Shinohara ET; Cao C; Niermann K; Mu Y; Zeng F; Hallahan DE; Lu B
Oncogene; 2005 Aug; 24(35):5414-22. PubMed ID: 15940265
[TBL] [Abstract][Full Text] [Related]
10. The androgen receptor is a negative regulator of eIF4E phosphorylation at S209: implications for the use of mTOR inhibitors in advanced prostate cancer.
D'Abronzo LS; Bose S; Crapuchettes ME; Beggs RE; Vinall RL; Tepper CG; Siddiqui S; Mudryj M; Melgoza FU; Durbin-Johnson BP; deVere White RW; Ghosh PM
Oncogene; 2017 Nov; 36(46):6359-6373. PubMed ID: 28745319
[TBL] [Abstract][Full Text] [Related]
11. CGP57380 enhances efficacy of RAD001 in non-small cell lung cancer through abrogating mTOR inhibition-induced phosphorylation of eIF4E and activating mitochondrial apoptotic pathway.
Wen Q; Wang W; Luo J; Chu S; Chen L; Xu L; Zang H; Alnemah MM; Ma J; Fan S
Oncotarget; 2016 May; 7(19):27787-801. PubMed ID: 27050281
[TBL] [Abstract][Full Text] [Related]
12. [Mechanism underlying pancreatic cancer cell resistance to mTOR inhibitor RAD001 via c-Raf/ERK1/2 activation].
Wei F; Zhang P; Qi J; Wang M; Wang G
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jan; 30(1):23-7. PubMed ID: 24405594
[TBL] [Abstract][Full Text] [Related]
13. RAD001 enhances the radiosensitivity of SCC4 oral cancer cells by inducing cell cycle arrest at the G2/M checkpoint.
Yu CC; Hung SK; Liao HF; Lee CC; Lin HY; Lai HC; Li SC; Ho HC; Huang HB; Su YC
Anticancer Res; 2014 Jun; 34(6):2927-35. PubMed ID: 24922656
[TBL] [Abstract][Full Text] [Related]
14. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
15. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model.
Mabuchi S; Altomare DA; Cheung M; Zhang L; Poulikakos PI; Hensley HH; Schilder RJ; Ozols RF; Testa JR
Clin Cancer Res; 2007 Jul; 13(14):4261-70. PubMed ID: 17634556
[TBL] [Abstract][Full Text] [Related]
16. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
17. RAD001 (everolimus) attenuates experimental autoimmune neuritis by inhibiting the mTOR pathway, elevating Akt activity and polarizing M2 macrophages.
Han R; Gao J; Zhai H; Xiao J; Ding Y; Hao J
Exp Neurol; 2016 Jun; 280():106-14. PubMed ID: 27063582
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer.
Manegold PC; Paringer C; Kulka U; Krimmel K; Eichhorn ME; Wilkowski R; Jauch KW; Guba M; Bruns CJ
Clin Cancer Res; 2008 Feb; 14(3):892-900. PubMed ID: 18245553
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of Autophagy by Chloroquine Alone or in Combination with mTOR Inhibitors Induces Apoptosis in Neuroendocrine Tumor Cells.
Avniel-Polak S; Leibowitz G; Riahi Y; Glaser B; Gross DJ; Grozinsky-Glasberg S
Neuroendocrinology; 2016; 103(6):724-37. PubMed ID: 26619207
[TBL] [Abstract][Full Text] [Related]
20. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer.
Mabuchi S; Altomare DA; Connolly DC; Klein-Szanto A; Litwin S; Hoelzle MK; Hensley HH; Hamilton TC; Testa JR
Cancer Res; 2007 Mar; 67(6):2408-13. PubMed ID: 17363557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
